Should antibiotic prophylaxis before orthopedic implant surgery depend on the duration of pre-surgical hospital stay?

Marie Davat¹, Lydia Wuarin¹, Dimitrios Stafylakis¹, Mohamed Abbas², Stephan Harbarth², Didier Hannouche¹ and Ilker Uçkay³*

Abstract

Background: Prolonged hospital stay before surgery is a risk for colonization with antibiotic-resistant microorganisms and possible antibiotic-resistant surgical site infections (SSI), which lacks acknowledgement in international guidelines for perioperative antibiotic prophylaxis.

Method: Retrospective cohort study focusing on prophylaxis-resistant SSI in adult orthopedic implant patients; with emphasis on length of hospital stay prior to the index surgery.

Results: We enrolled 611 cases of SSI (median age, 65 years; 241 females and 161 immune-suppressed) in four large implant groups: arthroplasties (n = 309), plates (n = 127), spondylodeses (n = 31), and nails (n = 46). The causative pathogen was resistant to the perioperative antibiotic prophylaxis regimen in 307 cases (307/611; 50%), but the length of pre-surgical hospitalization did not influence the incidences of prophylaxis-resistant SSIs. These incidences were (107/211; 51%) for the admission day, (170/345; 49%) within 10 days of delay, (19/35; 54%) between 10 and 20 days, and (11/20; 55%) beyond 20 days of hospital stay before surgery. The corresponding incidences of methicillin-resistant staphylococci were 13%, 14%, 17%, and 5%, respectively. In adjusted group comparisons, the length of prior hospital stay was equally unrelated to future prophylaxis-resistant SSI (odds ratio 1.0, 95% confidence interval 0.99–1.01).

Conclusions: In our retrospective cohort of orthopedic implant SSI, the length of pre-surgical hospital stay was unrelated to the incidence of prophylaxis-resistant pathogens.

Keywords: Perioperative antibiotic prophylaxis, Implant orthopedic surgery, Length of hospital stay, Surgical site infections

Background

Prolonged hospital stay before orthopedic surgery is a potential risk for acquisition of antibiotic-resistant microorganisms [1]. Thus in case of delayed surgery and surgical site infections (SSI) [2], the SSI might be multi-resistant or resistant to the perioperative antibiotic prophylaxis that was administered during the index operation. For example in our hospital, lengthening of hospital stay by one additional day was associated with a 5% increment of new MRSA carriage [1]. Moreover, prophylaxis-resistant germs may remain undetected except for outbreak situations or scientific studies [3]. This possible threat not only concerns methicillin-resistant Staphylococcus aureus (MRSA) [2, 3], but also methicillin-resistant coagulase-negative staphylococci [4], cephalosporin-resistant enterococci [5], non-fermenting Gram-negative rods [6] or extended-spectrum β-lactamase (ESBL) producing rods [7]. These pathogen groups all escape to standard prophylaxis with first-and second generation cephalosporins [2]. Especially, implant-related orthopedic surgery [8] is prone to SSI by methicillin-resistant staphylococci [4].

Many colleagues administer vancomycin or other broad-spectrum agents as prophylaxis, alone or in combination, for patients with long hospital stays (personal
communication). There are no data supporting this practice. National [9] and international [10] guidelines and consensus meetings [11] do not provide robust evidence on the choice of the prophylactic agent upon the length of pre-surgical stay. Indeed, international experts unanimously advocate single-dose cephalosporins or vancomycin for any orthopedic procedures [9–12].

In this retrospective cohort analysis, we specifically link the duration of pre-surgical hospital stay to the antibiotic resistance profile of orthopedic implant-related SSIs. We do not compute SSI risks or report treatment successes that we already have published elsewhere [13–15].

Methods
The Geneva University Hospitals is a tertiary center with a long tradition of clinical research regarding prevention of orthopedic implant-related infections [8]. The most recent prevalence of methicillin-resistant *Staphylococcus aureus* (MRSA) and methicillin-resistant coagulase-negative staphylococci among the clinical isolates in the orthopedic service were 11% [13] and 75% [4, 16], respectively. The hospital recommends a single intravenous dose of pre-operative cefuroxime 1.5 g as standard prophylaxis in orthopedic surgery and traumatology. Only for cases with convincing history of penicillin allergy [17] or past/present MRSA carriage [3], we recommend one dose of vancomycin 1 g intravenously. Discipline regarding these recommendations is very good, with only maximal 5–10% deviations according to the last control assessments. We currently lack a universal policy for searching and decolonizing *S. aureus* body carriage before surgery. Positive urinary or anal carriage of ESBL [7] does not alter our recommendations for orthopedic surgery. If surgery lasts for more than 4 h, prophylaxis is repeated. In selected cases, surgeons may continue it up to 24 h; except for open fractures with longer durations of preemptive treatment [18]. Since 2016, the standard dose was doubled for obese patients with more than 100 kg weight [19]. In selected cases, surgeons also implement arthroplasties with or without aminoglycoside-containing cement.

For the actual study, we used a composite database (Ethical Committee no. 13–178, 08–057 [13], 08–061 [20], and 14–198), including all adult patients with orthopedic implant SSI [8] and a minimal follow-up of two years [1]. We excluded cases that were amputated [21], orthopedic surgery cases without implants, community-acquired infections, recurrent episodes of the same infection and all patients necessitating actual or recent systemic antibiotic administration during the last 2 weeks. Our SSI definitions were based on the Center of Disease Control standards [22]. Basically, any infection within 1 year of implantation was a SSI, unless proven otherwise; e.g. by clear evidence of a hematogenous [23] or lymphogenous origins [24]. We defined hospital stay as a hospitalization in acute care settings. Consequently, we considered long-term care facilities not as hospitals. We collected several microbiological samples from pus or deep intraoperative tissues, and ignored results of superficial specimens or of a sinus tract. The microbiology laboratory processed all specimens according to Clinical and Laboratory Standard's Institute recommendations [25], before switching to the EUCAST criteria (European Committee) in 2014 [26].

Statistical analyses
Our primary objective was to assess the association between the length of prior hospital stay to future SSIs that were resistant to standard antibiotic prophylaxis (cefuroxime or vancomycin). We performed group comparisons using the Pearson-$\chi^2$ or the Wilcoxon-ranksum-test. An unmatched multivariate logistic regression analysis determined associations with the outcome “SSI resistant to standard prophylaxis”. We introduced independent variables with a $p$ value $\leq 0.05$ in the univariate analysis stepwise into the multivariate analysis, except for length of prior hospital stay, which we forced into the final model. We arbitrarily categorized the length of hospital stay individually for the days 0, 1, 2, 3, 4, for the groups between 5 and 9 days, 10–20 days, and more than 20 days; and plotted them against the occurrence of resistant SSIs. We used STATA software (9.0, STATA™, USA) and considered $p$ values $\leq 0.05$ (two-tailed) as significant.

Results
We included 611 orthopedic SSI cases meeting our study criteria (among 611 patients, 241 females (39%) and including 161 immune-suppressed persons (27%): diabetes mellitus ($n = 73$), active cancer (40), severe chronic alcoholism (25), medicamentous immune-suppression (20), cirrhosis CHILD C (11), dialysis (4), solid organ transplantation (1), or a combination of different immune-suppressed states. Upon diagnosis, the median age of the patients was 65 years and the median serum C-reactive protein levels were 83 mg/L. The presence of soft-tissue abscesses and bacteremia complicated the infections in 73 (12%) and 98 (16%) episodes, respectively. The infected implants were: arthroplasties ($n = 309$), plates (127), spondylodines (31) [27], nails (46) [15], and various others (98). In 25 episodes, the infection occurred in the foot. Our laboratory detected 84 different microbiological constellations with the five most frequently identified pathogens being *Staphylococcus aureus* ($n = 166$), streptococci (46), Gram-negatives [6] (140; with 80 non-fermenters including 42 *Pseudomonas aeruginosa* cases, and 24 anaerobes [28]), enterococci [5] (33), *S. lugdunensis* [16] (9), and skin commensals (134). In 100 cases, SSI were polymicrobial and in 35 cases culture-negative [29].
Associations with previous hospital stay
Overall, 556 (90%) implant surgeries with subsequent SSI were performed within 10 days after admission, 35 between 10 to 20 days, and 20 after 20 days since admission. Formally, the study population was already hospitalized during a median delay of 1 day (range, 0–178 d, interquartile range, 0–3 d) before the index surgery, and 44 patients had previously known MRSA carriage [3]. The prophylactic regimens followed the institutional standards for the majority of cases, but we detected the following deviations: several doses of cefuroxime (n = 30), use of ciprofloxacin (1), amoxicillin/clavulanic acid (1), clindamycin (1), and cefazolin (1). Overall, 36 patients received vancomycin, of which 28 episodes because of previous positive MRSA carriage in the past, and 8 probably because of presumed beta-lactam allergy or beta-lactam intolerance of various nature. In contrast, 16 former MRSA carriers lacked vancomycin for which the reasons were unknown. In 33 episodes (5%), we ignored the agent of prophylaxis, which was classified as "usual" according to the records.

Overall, the causative pathogen of future SSI was resistant to prior prophylaxis in 307 cases (307/611; 50%) (Table 1), but lacked association to previous length of pre-surgical hospitalization. The incidences of resistant pathogens were (107/211; 51%) for surgeries performed on the day of admission, (89/200; 45%) on Day 1, (24/41; 59%) on Day 2, (25/40; 63%) on Day 3, (9/17; 53%) on Day 4, (18/39; 46%) between 5 and 9 days since admission, (24/43; 56%) between 10 and 20 days, and (11/20; 55%) beyond 20 days after admission. The corresponding incidences of SSI due to methicillin-resistant staphylococci were 13% (27/211), 10% (19/200), 24% (10/41), 20% (8/40), 24% (4/17), 13% (5/39), 21% (9/43) and 5% (1/20), respectively. Figure 1 display the proportion graphically and denies the existent of a threshold in the number of days of hospital stay prior to surgery and subsequent prophylaxis-resistant and methicillin-resistant SSIs. The proportion of aminoglycoside-resistant SSI (that we computed because of possible cemented arthroplasty) was very low (3 of 611 cases; 1%). A (past) history of MRSA and lack of vancomycin prophylaxis was the only variable related to multi-resistant SSI.

Multivariate adjustment
In view of the considerable case-mix, we performed an adjusted logistic regression analysis. Here, the length of prior hospital stay was equally unrelated to prophylaxis-resistant SSI as a continuous variable (odds ratio 1.0, 95% confidence interval 0.99–1.01) or when breaking down to various stratifications (Table 2). Also, in this regression analysis, and unlike the former crude group comparison, immune-suppression lacked associations with prophylaxis-resistant SSI. The goodness-of-fit testing of our final model was non-significant (p = 0.31).

Discussion
In our cohort of orthopedic implant infections among adult patients, the length of hospital stay before the index surgery (implantation) was unrelated to the risk of future SSI due to prophylaxis-resistant pathogens such as methicillin-resistant staphylococci [4, 13]. Therefore, we argue against the broadening of the antibiotic prophylaxis with second-generation cephalosporins towards combinations that include more Gram-positive or

Table 1 Comparisons of demographic and clinical variables of adult orthopaedic implant patients with future surgical site infections resistant to the prophylactic regimen of the index surgery versus prophylaxis-susceptible surgical site implant infections

|                     | Susceptible to prior prophylaxis | Resistant to prior prophylaxis |
|---------------------|----------------------------------|-------------------------------|
| Total n = 611       | n = 304                          | n = 307                       |
| Female sex          | 118 (39%)                        | 123 (40%)                     |
| Age (median)        | 67 years                         | 62 years                      |
| Past history of MRSA\* body carriage | 12 (4%)           | 32 (10%)                     |
| Immune suppression\* | 91 (30%)                        | 70 (23%)                      |
| - diabetes mellitus | 45 (15%)                         | 28 (9%)                       |
| Shoulder implants   | 12 (4%)                          | 7 (2%)                        |
| Arthroplasties      | 147 (48%)                        | 162 (53%)                     |
| Spondylodeses       | 14 (5%)                          | 17 (6%)                       |
| Plates              | 66 (22%)                         | 61 (20%)                      |
| Intramedullary nails | 20 (7%)                       | 26 (8%)                       |
| Foot osteosyntheses | 15 (5%)                          | 10 (3%)                       |
| Duration of prior hospital stay (median) | 1 day (range, 0–178 d) | 1 day (range, 0–68 d) |

\*Significant p values ≤0.05 are displayed in bold and italic
\*Immune suppression = diabetes mellitus, corticosteroid medication, organ transplantation, cirrhosis CHILD C, dialysis, or active cancer
\*Methicillin-resistant Staphylococcus aureus
Gram-negative coverage. One might argue, whether the study question is of importance. International recommendations are clear and do not recommend this [1, 2]. And yet, according to our experience, many surgeons or physicians often broaden the prophylaxis against official recommendations. Regarding prophylactic issues, our center shows high compliance and the study population is homogenous. Hence, we could easily perform our study by avoiding major confounding and substantial interactions, making the interpretations more difficult.

In the literature, many research groups investigated the influence of a delay between admission and surgery with the occurrence of subsequent infection and its pathogen profile. However, these studies concerned open fractures, with time delays ranging from 0 to 24 h [18]. We found only one study specifically linking longer hospitalization delays with healthcare-associated infections [30]. In this study from Brazil, patients with nosocomial infections due to MSSA (not only orthopedic implants) revealed a median delay of prior hospital stay of 9 days, compared to MRSA infections with a past median delay of 18 days [30].

![Fig. 1 Proportions of future resistant pathogens to standard prophylaxis (vertical axis) according to the delay between admission and the index implant surgery (horizontal axis). The corresponding trend lines are almost horizontal.](image)

| Table 2 | Univariate and multivariate analyses of factors potentially related to antibiotic prophylaxis-resistant surgical site infections (Logistic regression analysis; results expressed as odds ratios with 95% confidence intervals) |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Total n = 611                                                                 |                                                                                                                                    |
|         | Univariate analysis                                                                                                                                   | Multivariate analysis                                                                                                           |
| Female sex | 1.0, 0.7–1.4                                                                                                                                             | n.d.                                                                                                                                |
| Age       | 1.0, 1.0–1.0                                                                                                                                             | 1.0, 1.0–1.0                                                                                                                        |
| Past history of MRSA<sup>b</sup> body carriage | **1.3, 1.1–2.9**                                                                                                                   | **1.4, 1.1–3.3**                                                                                                                    |
| Immune suppression<sup>a</sup> | 0.7, 0.5–1.1                                                                                                                                             | n.d.                                                                                                                                |
| - Diabetes mellitus | 0.7, 0.4–1.2                                                                                                                                             | n.d.                                                                                                                                |
| Shoulder implants | 0.5, 0.2–1.5                                                                                                                                             | n.d.                                                                                                                                |
| Arthroplasties | 1.1, 0.8–1.8                                                                                                                                             | 1.2, 0.8–1.9                                                                                                                        |
| Spondylodiseses | 1.4, 0.7–2.9                                                                                                                                             | 1.4, 0.6–3.1                                                                                                                        |
| Plates    | 1.0, 0.6–1.5                                                                                                                                             | n.d.                                                                                                                                |
| Intramedullary nails | 1.2, 0.6–2.3                                                                                                                                             | 1.3, 0.6–2.6                                                                                                                        |
| Foot osteosyntheses | 0.7, 0.3–1.6                                                                                                                                             | 0.8, 0.3–1.9                                                                                                                        |
| Duration of prior hospital stay |                                                                                                                                     |                                                                                                                                    |
| - 10–20 days compared to ≤10 days | 1.1, 0.5–2.4                                                                                                                                             | 1.2, 0.5–2.5                                                                                                                        |
| - ≥ 20 days compared to ≤10 days | 1.0, 0.6–1.7                                                                                                                                             | 1.1, 0.4–3.3                                                                                                                        |

<sup>a</sup>Statistically significant results are displayed in **bold and italic**

<sup>b</sup>Methicillin-resistant *Staphylococcus aureus*

<sup>c</sup>Immune suppression = diabetes mellitus, corticosteroid medication, organ transplantation, cirrhosis CHILD C, dialysis, or active cancer

<sup>d</sup>Statistical significant results are displayed in **bold and italic**

<sup>e</sup>Methicillin-resistant *Staphylococcus aureus*
In contrast, the literature is full of opinion papers and retrospective studies investigating the possibility of better outcomes with broader prophylaxis. The propositions of the authors differ from one paper to another and focus on different strategies which are: continuing the prophylaxis beyond a single dose [31, 32], augmenting of doses [19], combining with local prophylaxis [33, 34] (especially local vancomycin in spine surgery [35]), double prophylaxis [36] against Gram-negative [37]. Gram-positive [38, 39], methicillin-resistant strains [4] and anaerobes [28], or by investigating the performance of universal glycopeptid prophylaxis [40–42]. In summary, the majority of these enhancements failed to reduce SSI risk, at least not in orthopedic surgery [34, 39–42]. Exceptions remain rare [32, 37], very specific and often not reproducible by other research groups [12, 31, 36]. Branch-Elliman et al. estimated that the number of orthopedic cases needed to prevent one Gram-positive SSI with vancomycin would be 1:53 for known MRSA carriers, compared to 1:176 for unknown carriers [39]. Also, concomitant colonization with MRSA does not always protect from colonization by susceptible S. aureus (MSSA) strains [1].

Broader antibiotic prophylaxis can be harmful, especially with prophylactic aminoglycosides against Gram-negative pathogens [38, 39]. Numerous studies reported transient kidney injuries by aminoglycosides [39] or combined vancomycin prophylaxis [12] in orthopedic surgery. The risk for antibiotic-resistant organisms seems to be negligible [35]. Walker et al. reported that following a change in prophylaxis (from floxacillin & gentamycin to amoxicillin/clavulanic acid), they witnessed a 63% decrease in post-operative renal insufficiencies [43]. In 2009, Scotland issued a target to reduce Clostridium difficile outbreaks. Consequently, hospitals changed prophylaxis from a cephalosporin to gentamicin-containing regimens (4 mg/kg), resulting in a 94% increase in kidney injuries [38].

Besides the fact that our study is retrospective, it has several limitations. First, we excluded already infected cases. Hence, we can only address the risk of prophylaxis-resistant SSI, but we cannot compare between infected and non-infected populations, or with patients who were under systemic antibiotic selection for any reason. Second, our orthopedic service has no policy of pre-surgical S. aureus [2] decolonization. Such a strategy might alter the association between the length of hospital stay and the patterns of subsequent SSI. Third, we assume like many other colleagues that most SSIs origin in the operating theatre [2], and that the length of hospital stay is a surrogate of nosocomial acquisitions of resistant pathogens. In our daily clinical practice, we usually neglect to assess individual colonization throughout the hospital stay. This assumption might not be granted. Studies from Sweden suggest a mounting colonization pressure by methicillin-resistant staphylococci after two to three days [4] post-admission, and ESBL acquisitions in orthopedic wards has also been demonstrated [7], i.e. during wound care or wound breakdowns. Regarding these ward-born SSIs, the perioperative antibiotic prophylaxis during the index surgery would naturally lack influence; which we equally cannot control for in our retrospective analysis. Fourth, in our tertiary center, we use cefuroxime as standard antibiotic prophylaxis for many surgical disciplines, instead of cefazolin, which is another recommended agent in most guidelines for orthopedic surgeries. Most experts would agree that the difference and ecological impact between the two second-generation cephalosporins would be minimal, as they are close molecules in terms of clinical spectrum and efficacy. Although we cannot formally pronounce on the hypothetical results of our study performed under cefazolin, we nevertheless would expect the same results. Fifth, most of our patients had surgery within few days since admission, with a median delay of only 1 day. From a microbiological point of view, it seems rather unlikely that such a short hospitalization changes colonization with antibiotic-resistant germs. Nevertheless, we intended to study real-life conditions without selection biases. Theoretically, we could have performed a study only with those patients operated after 1 week of hospital stay or longer. This would, however, introduce a major bias and a very small and too specific study population, which we avoided. Sixth, many our implant infections were due to coagulase-negative staphylococci and other skin commensals. Usually, these bacteria are often regarded as contaminants. In our study, all bacterial results stem from several deep intraoperative tissue specimens, making contamination unlikely. Moreover, skin commensals, including coagulase-negative staphylococci and especially S. epidermidis, are frequent pathogens of low-grade orthopedic implants [8, 14–16] due to their ability to perform biofilms [44]. Lastly, we cannot retrospectively enumerate the individual reasons for a delayed surgery. As simple as it seems, in a retrospective study this question is very difficult to be answered. The reasons may vary between lack of operation slots, triage issues, lack of patient’s and family’s consent, nosocomial fractures occurring during a hospital stay for another reason, availability of the individual surgeon, week-ends and holidays, non-availability of the specific osteosynthesis material, or a panoply of combined reasons. However, we do not think that the individual reason for delay would have influenced our findings in this large epidemiological study.

Conclusions
According to our retrospective cohort analysis, a long pre-surgical hospital stay was not associated with more prophylaxis-resistant SSIs, in 611 adult patients undergoing orthopedic implant surgery, when compared to those with prophylaxis-susceptible pathogens. We keep
our antibiotic perioperative prophylaxis policy as it is, regardless of the duration of pre-surgical length of hospital stay.

Acknowledgements
We thank the teams of the Laboratory of Bacteriology and the Orthopedic Service for support.

Funding
None.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions
MD, LW, DH, and IU conceived and designed the study. DH and SH were major contributors in writing and supervising the manuscript. MD, LW, DS treated most patients and supervised the study. MD and IU performed the data analysis. All authors read and approved the final manuscript.

Ethics approval and consent to participate
This retrospective study based on four composite databases, which were all approved by the local research ethics committee. The processing of patients’ personal data was anonymized and complied with local data protection legislations. As no individual data is published as well as no intervention was personal data was anonymized and complied with local data protection.

Consent for publication
No applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Orthopedic Surgery Service, Geneva University Hospitals, Geneva, Switzerland. 2Infection Control Program, Geneva University Hospitals, Geneva, Switzerland. 3Infectiology, Balgrist University Hospital, Forchstrasse 340, 8008 Zürich, Switzerland.

Received: 20 September 2018 Accepted: 11 October 2018

Published online: 08 November 2018

References
1. Landelle C, Iten A, Uçkay I, Sax H, Camus V, Cohen G, Renzi G, et al. Does colonization with methillin-susceptible Staphylococcus aureus protect against nosocomial acquisition of methillin-resistant S. aureus? Infect Control Hosp Epidemiol. 2014;35:527–33.
2. Uçkay I, Hoffmeyer P, Lew D, Pittet D. Prevention of surgical site infections in orthopaedic surgery and bone trauma: state-of-the-art update. J Hosp Infect. 2013;84:12–
3. Uçkay I, Sax H, Iten A, Camus V, Renzi G, Schenkel J, et al. Effect of screening for methillin-resistant Staphylococcus aureus carriage by polymerase chain reaction on the duration of unnecessary preemptive contact isolation. Infect Control Hosp Epidemiol. 2008;29:1077–9.
4. Uçkay I, Harbarth S, Ferry T, Lübbecke A, Emonet S, Hoffmeyer P, et al. Methillin-resistant in orthopaedic coagulase-negative staphylococcal infections. J Hosp Infect. 2011;79:248–53.
5. Uçkay I, Pires D, Agostinho A, Guanzon N, Ozturk M, Bartalone P, et al. Enterococci in orthopaedic infections: who is at risk getting infected? J Inf Secur. 2017;75:309–14.
6. Jamei O, Gjoni S, Zenelaj B, Kressmann B, Belaieff W, Hannouche D, et al. Which Orthopaedic patients are infected with gram-negative non-fermenting rods? J Bone Jt Infect. 2017;2:73–6.
7. Agostinho A, Renzi G, Haustein T, Jourdau G, Bonfillon C, Rougemont M, et al. Epidemiology and acquisition of extended-spectrum beta-lactamase-producing Enterobacteriaceae in a septic orthopedic ward. SpringerPlus. 2013;2:91.
8. Cuerel C, Abrasart S, Billières J, Andrey D, Suvà D, Dubois-Feniolle V, et al. Clinical and epidemiological differences between implant-associated and implant-free orthopaedic infections. Eur J Orthop Surg Traumatol. 2017;27:229–31.
9. Bratzler DW, Dellinger EP, Olsen KM, Perl TM, Auwaerter PG, Maureen K, Bolon MK, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health Syst Pharm. 2013;70:195–283.
10. WHO Global guidelines for the prevention of surgical site infections. WHO. In: Geneva; 2016.
11. Parvizi J, Gehrke T, Chen AF. Proceedings of the international consensus meeting on Periprosthetic joint infection. Bone Joint J. 2013;95-B:1450–2.
12. Courtey PM, Melnic CM, Zimmer Z, Anati J, Lee GC. Addition of Vancomycin to Cefazolin prophylaxis is associated with acute kidney injury after primary joint Arthroplasty. Clin Orthop Relat Res. 2015;473:2197–203.
13. Uçkay I, Lübbecke A, Harbarth S, Emonet S, Tovmizanava L, Agostinho A, et al. Low risk despite high endemicity of methillin-resistant Staphylococcus aureus infections following elective total joint arthroplasty: a 12-year experience. Ann Med. 2012;44:360–8.
14. Teterycz D, Ferry T, Lew D, Stern R, Assal M, Hoffmeyer P, et al. Outcome of orthopedic implant infections due to different staphylococci. Int J Infect Dis. 2010;14:913–8.
15. AhMayahi M, Betz M, Müller DA, Stern R, Tahintzi P, Bernard L, et al. Remission rate of implant-related infections following revision surgery after fractures. Int Orthop. 2013;37:2253–8.
16. Mohamad M, Uçkay I, Hannouche D, Mozzaire H. Particularities of Staphylococcus lugdunensis in orthopaedic infections. Infect Dis (Lond). 2018;60:223–7.
17. Tan TL, Springer BD, Ruder JA, Ruffolo MR, Chen AF. Is Vancomyc-in only prophylaxis for patients with penicillin allergy associated with increased risk of infection after Arthroplasty? Clin Orthop Relat Res. 2016;474:1601–6.
18. Gonzalez A, Suvà D, Dunkel N, Nicodeme JD, Lomessy A, Lauper N, et al. Are there clinical variables determining antibiotic prophylaxis-susceptible versus resistant infection in open fractures? Int Orthop. 2014;38:2323–7.
19. Lübbecke A, Zingg M, Vu D, Mozziari HH, Christofilopoulos P, Uçkay I, et al. Body mass and weight thresholds for increased prosthetic joint infection rates after primary total joint arthroplasty. Acta Orthop. 2016;87:132–8.
20. Jugun K, Vaudaux P, Garbino J, Pagan L, Hoffmeyer P, Lew D, et al. The safety and efficacy of high-dose daptomycin combined with rifampin for the treatment of gram-positive osteoartricular infections. Int Orthop. 2013;37:1375–80.
21. Dunkel N, Belaieff W, Assal M, Corvi V, Karaça S, Laczáta A, et al. Wound dehiscence and stump infection after lower limb amputation: risk factors and association with antibiotic use. J Orthop Sci. 2012;17:588–94.
22. Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Guideline for prevention of surgical site infection, 1999. Centers for Disease Control and Prevention (CDC). Hospital Infection Control Practices Advisory Committee. Am J Infect Control. 1999;27:97–132.
23. Uçkay I, Lübbecke A, Emonet S, Tovmizanava L, Stern F, Ferry T, et al. Low incidence of haematogetic seeding to total hip and knee prostheses in patients with remote infections. J Inf Secur. 2009;59:337–45.
24. Sendi P, Christenson B, Uçkay I, Trampuz A, Achermann Y, Boggian K, et al. Group B streptococcus in prosthetic hip and knee joint-associated infections. J Hosp Infect. 2011;79:64–9.
25. Performance Standards for Antimicrobial Susceptibility Testing: 17th Informational Supplement. Clinical and Laboratory Standards Institute. Pennsylvania; USA: Wayne; 2007.
26. European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs. Version. 2014. http://www.eucast.org/clinical_breakpoints.
27. Billières J, Uçkay I, Faundez A, Douissard J, Kuczma P, Suvà D, et al. Variables associated with remission in spinal surgical site infections. J Spine Surg. 2016;2:128–34.
28. Lebowitz D, Kressmann B, Gjoni S, Zenelaj B, Grosgurin O, Marti C, et al. Clinical features of an aerobac orthopaedic infections. Infect Dis (Lond). 2017;49:137–40.
29. Al-Mayahi M, Cian A, Lipsky BA, Suvà D, Müller C, Landelle C, et al. Administration of antibiotic agents before intraoperative sampling in orthopaedic infections alters culture results. J Inf Secur. 2015;7:518–25.
30. Baraboski IG, Tsagalou EP, Papakonstantinou I, Marangos MN, Gogos C, Skoulletis AT, et al. Length of exposure to the hospital environment is more important than antibiotic exposure in healthcare associated infections by methillin-resistant Staphylococcus aureus: a comparative study. Braz J Infect Dis. 2011;15:426–35.
31. Nadeem RD, Akhtar M, Cheema OI, Hashmi AR, Nadeem MJ, Nadeem A. Antibiotic prophylaxis in hip surgery: a comparison of two vs. three doses of cefuroxime. J Pak Med Assoc. 2015;65:136–41.

32. Engesaeter LB, Lie SA, Espehaug B, Furnes O, Vollset SE, Havellin LI. Antibiotic prophylaxis in total hip arthroplasty: effects of antibiotic prophylaxis systemically and in bone cement on the revision rate of 22,170 primary hip replacements followed 0-14 years in the Norwegian Arthroplasty register. Acta Orthop Scand. 2003;74:644–51.

33. O’Toole RV, Joshi M, Carlini AR, Murray CK, Allen LE, Scharfstein DO, et al. Local antibiotic therapy to reduce infection after operative treatment of fractures at high risk of infection: a multicenter, randomized, controlled trial (VANCO study). J Orthop Trauma. 2017;31:18–24.

34. Westberg M, Frihagen F, Brun OC, Figved W, Greggaard B, Valland H, et al. Effectiveness of gentamicin-containing collagen sponges for prevention of surgical site infection after hip arthroplasty: a multicenter randomized trial. Clin Infect Dis. 2015;60:1752–9.

35. Chotai S, Wright PW, Hale AT, Jones WA, McGitt MJ, Patt JC, et al. Does Intrawound Vancomycin application during spine surgery create Vancomycin-resistant organism? Neurosurgery. 2017;80:746–53.

36. Burger J, Hansen BJ, Leary EV, Aggarwal A, Keeney JA. Dual-agent antibiotic prophylaxis using a single preoperative Vancomycin dose effectively reduces prosthetic joint infection rates with minimal renal toxicity risk. J Arthroplast. 2018;33:213–8.

37. Bosco JA, Tejada PRR, Catanzano AJ, Stachel AG, Phillips MS. Expanded gram-negative antimicrobial prophylaxis reduces surgical site infections in hip Arthroplasty. J Arthroplast. 2016;31:616–21.

38. Bell S, Davey P, Nathwani D, Marwick C, Vadveloo T, Sneddon J, et al. Risk of AKI with gentamicin as surgical prophylaxis. J Am Soc Nephrol. 2014;25:2625–32.

39. Branch-Elliman W, Ripollone JE, O’Brien WJ, Itani KMF, Schweizer ML, Perencevich E, et al. Risk of surgical site infection, acute kidney injury, and Clostridium difficile infection following antibiotic prophylaxis with vancomycin plus a beta-lactam versus either drug alone: a national propensity-score-adjusted retrospective cohort study. PLoS Med. 2017;14:1002340.

40. Cranney G, Elliott R, Weatherly H, Chambers D, Hawkins N, Myers L, et al. A systematic review and economic model of switching from non-glycopeptide to glycopeptide antibiotic prophylaxis for surgery. Health Technol Assess. 2008;12:1–147.

41. Mini E, Nobili S, Periti P. Methicillin-resistant staphylococci in clean surgery. Is there a role for prophylaxis? Drugs. 1997;54:39–52.

42. Crawford T, Rodvold KA, Solomkin JS. Vancomycin for surgical prophylaxis? Clin Infect Dis. 2012;54:1474–9.

43. Walker H, Patton A, Bayne G, Marwick C, Sneddon J, Davey P, et al. Reduction in post-operative acute kidney injury following a change in antibiotic prophylaxis policy for orthopaedic surgery: an observational study. J Antimicrob Chemother. 2016;71:2598–605.

44. Uçkay I, Pittet D, Vaudaux P, Sax H, Lew D, Waldvogel F. Foreign body infections due to Staphylococcus epidermidis. Ann Med. 2008;40:1–11.